Immunocore Holdings plc (IMCR) Stock
7 of the hedge funds AlphaScala tracks reported IMCR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $50.71M.
Which hedge funds own IMCR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.60M | $50.71M | +29% |
| Point72 Steve Cohen | 990K | $31.44M | -10% |
| Marshall Wace | 591K | $18.76M | +228% |
| Citadel Ken Griffin | 567K | $17.99M | +146% |
| D.E. Shaw David Shaw | 405K | $12.86M | +21% |
| Renaissance Technologies Jim Simons (founder) | 102K | $3.25M | -38% |
| Bridgewater Associates Ray Dalio | 37K | $1.17M | +94% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →IMCR price chart
Powered by TradingViewWhat does Immunocore Holdings plc do?
Immunocore Holdings plc is a leading biotechnology company that specializes in the development of T cell receptor (TCR) therapies, holding a significant promise in treating various types of cancer, autoimmune disorders, and infectious diseases. As an American Depository Receipt (ADR), it provides US investors an opportunity to invest in foreign stocks, specifically this innovative UK-based company, without the complexities of dealing with a foreign market. Immunocore is known for its groundbreaking research in ImmTAC technology, a unique modality that effectively links TCRs with immune effectors to target and dismantle cancerous cells. The company has been a pioneer in the immunotherapy sector, contributing notably to the field's advancements. Its ADR facilitates an accessible means for investors looking to explore high-growth potential within the biotechnology industry, specifically in the immunotherapy sector, which plays a crucial role in addressing unmet medical needs. Immunocore Holdings plc continues to leverage its scientific expertise to develop cutting-edge therapeutics that could revolutionize treatment paradigms across critical medical challenges worldwide.